10/19/20 7:00 AMNasdaq : XAIR Beyond Air® Presents Pilot Bronchiolitis Data at the CHEST Annual Meeting 2020150 ppm nitric oxide was statistically significant compared to both control and 85 ppm nitric oxide arms on the primary and key secondary endpoints All treatment groups had similar safety profiles and nitric oxide w as well tolerated with no drug-related serious adverse event s observed GARDENRHEA-AIneutral
10/16/20 8:00 AMNasdaq : XAIR clinical trialBeyond Air® Presents Positive New Preclinical Data for the Use of a Single Injection of Gaseous Nitric Oxide as a Novel In situ Cancer VaccinationBeyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections andRHEA-AIneutral
09/11/20 8:00 AMNasdaq : XAIR conferencesBeyond Air to Present at the Oppenheimer & Co. Fall Healthcare Life Sciences and MedTech SummitBeyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections andRHEA-AIneutral
09/09/20 8:00 AMNasdaq : XAIR conferencesBeyond Air® to Present Posters on CoronaVirus and Bronchiolitis at the CHEST 2020 Annual MeetingBeyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections andRHEA-AIneutral
08/27/20 8:00 AMNasdaq : XAIR conferencesBeyond Air® to Present New Nitric Oxide Data in an e-Poster Presentation at the North America Conference on Lung Cancer 2020 (NACLC 2020)Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections andRHEA-AIneutral
08/10/20 4:01 PMNasdaq : XAIR Beyond Air Publishes New Data on Nitric Oxide to Treat M. Abscessus in the Peer-Reviewed Journal Access MicrobiologyHeterogeneity in M. abscessus susceptibility toRHEA-AInegative
08/06/20 7:45 AMNasdaq : XAIR earningsBeyond Air® Reports Financial Results for First Quarter of Fiscal Year 2021 and Provides Business UpdateU.S. COVID-19 study showing positive safety profile for patients enrolled toRHEA-AIneutral
07/23/20 8:00 AMNasdaq : XAIR earningsBeyond Air® to Announce Fiscal First Quarter 2021 Financial Results on Thursday, August 6thConference call at 8:30 a.m. ET Conference call at 8:30 a.m. ETRHEA-AIneutral
06/22/20 4:01 PMNasdaq : XAIR earningsBeyond Air Reports Financial Results for Fiscal Fourth Quarter and Year-End 2020Reported positive clinical data for third bronchiolitis study using high concentration nitric oxide, achieving primary and key secondary endpointsRHEA-AIneutral
06/08/20 5:29 PMNasdaq : XAIR earningsBeyond Air™ Scheduled to Announce Fiscal Year 2020 Financial Results on Monday, June 22ndConference call scheduled for Monday, June 22nd, at 4:30 p.m. Eastern Time Conference call scheduled for Monday, June 22nd, at 4:30 p.m. Eastern TimeRHEA-AIneutral